Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis
10.1093/neuonc/nos076 · doi-reference
Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: a modified Delphi approach to build international consensus-based definitions - International Pediatric Low-Grade Glioma Coalition
10.1093/neuonc/noae074 · doi-reference
Safety and efficacy of focused ultrasound induced blood-brain barrier opening for drug delivery in brain tumors
10.1038/s41582-020-00418-z · doi-reference
Is the blood-brain barrier really disrupted in all glioblastomas? A critical review of preclinical and clinical data
10.1093/neuonc/nox175 · doi-reference
Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain
10.1017/s1462399411001888 · doi-reference
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
10.1038/nature13121 · doi-reference
(V600E)BRAF is associated with feedback inhibition of receptor tyrosine kinases and sensitivity to MAP kinase pathway inhibitors
10.1073/pnas.0900780106 · doi-reference
IDH mutated low grade glioma in childhood and the impact of early inhibitor use: an international registry study
10.1093/neuped/wuag026.136 · doi-reference
Vorasidenib in IDH1- or IDH2-mutant low-grade glioma
10.1056/nejmoa2304194 · doi-reference
Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct epigenetic subtype with a poor prognosis
10.1007/s00401-020-02243-6 · doi-reference
IDH-mutant gliomas in children and adolescents - from biology to clinical trials
10.3389/fonc.2024.1515538 · doi-reference
Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations
10.1158/2159-8290.cd-18-0484 · doi-reference
Efficacy and safety of entrectinib in locally advanced or metastatic NTRK fusion-positive solid tumors: integrated analysis of three clinical trials
10.1016/s1470-2045(19)30691-6 · doi-reference
Integrated molecular meta-analysis of 1,000 pediatric high-grade and midline gliomas
10.1016/j.ccell.2017.08.017 · doi-reference
Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression
10.1073/pnas.2006076117 · doi-reference
Histone H3.3 G34R/V mutations promote aberrant PRC2 activity in cis through H3K36 methylation
10.1126/science.aac7272 · doi-reference
Hotspot H3F3A mutations define distinct epigenetic and biological subgroups of pediatric glioblastoma
10.1016/j.ccr.2012.08.024 · doi-reference
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
10.1038/nm.3855 · doi-reference
ONC201 (Dordaviprone) in recurrent H3 K27M-mutant diffuse midline glioma
10.1200/jco.23.01134 · doi-reference
10.1158/2159-8290.cd-23-0131
10.1158/2159-8290.cd-23-0131 · doi-reference
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201
10.1007/s11060-019-03271-3 · doi-reference
Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent ACVR1 mutations
10.1038/ng.2936 · doi-reference
Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma
10.1038/ng.2925 · doi-reference
Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytomas
10.1038/ng.2950 · doi-reference
Reduced levels of histone H3K27me3 and ACCN1 upregulation define a subset of pediatric diffuse intrinsic pontine gliomas
10.1016/j.ccr.2013.10.006 · doi-reference
Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma
10.1126/science.1232245 · doi-reference
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and nonbrainstem glioblastomas
10.1038/ng.1102 · doi-reference
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
10.1038/nature10833 · doi-reference
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
10.1093/neuonc/noac087 · doi-reference
Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase fusion-positive central nervous system tumors
10.1093/neuonc/noab090.168 · doi-reference
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
10.1016/s1470-2045(18)30119-0 · doi-reference
Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children
10.1056/nejmoa1714448 · doi-reference
Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma
10.1007/s11060-020-03592-8 · doi-reference
Neurofibromatosis type 1
10.1038/nrdp.2017.4 · doi-reference
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
10.1056/nejmoa1210093 · doi-reference
Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations
10.1056/nejmoa2303815 · doi-reference
Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas
10.1200/jco.2016.71.8726 · doi-reference
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
10.1038/s41591-023-02668-y · doi-reference
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas
10.1093/neuonc/nou059 · doi-reference
Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600-mutant low-grade glioma
10.1200/jco.22.01000 · doi-reference
